Protein network analysis reveals selectively vulnerable regions and biological processes in FTD by Bonham, Lw1 et al.
ARTICLE OPEN ACCESS
Protein network analysis reveals selectively
vulnerable regions and biological processes in
FTD
Luke W. Bonham, BS, Natasha Z.R. Steele, MPH, Celeste M. Karch, PhD, Claudia Manzoni, PhD,
Ethan G. Geier, PhD, Natalie Wen, Aaron Ofori-Kuragu, Parastoo Momeni, PhD, John Hardy, PhD,
Zachary A. Miller, MD, Christopher P. Hess, MD, PhD, Patrick Lewis, PhD, Bruce L. Miller, MD,
William W. Seeley, MD, Sergio E. Baranzini, PhD, Rahul S. Desikan, MD PhD, Raffaele Ferrari, PhD,
and Jennifer S. Yokoyama, PhD, on behalf of the International FTD-Genomics Consortium (IFGC)
Neurol Genet 2018;4:e266. doi:10.1212/NXG.0000000000000266
Correspondence
Dr. Yokoyama
jennifer.yokoyama@ucsf.edu
Abstract
Objective
The neuroanatomical profile of behavioral variant frontotemporal dementia (bvFTD) suggests
a common biological etiology of disease despite disparate pathologic causes; we investigated the
genetic underpinnings of this selective regional vulnerability to identify new risk factors for
bvFTD.
Methods
We used recently developed analytical techniques designed to address the limitations of
genome-wide association studies to generate a protein interaction network of 63 bvFTD risk
genes. We characterized this network using gene expression data from healthy and diseased
human brain tissue, evaluating regional network expression patterns across the lifespan as well
as the cell types and biological processes most affected in bvFTD.
Results
We found that bvFTD network genes show enriched expression across the human lifespan in
vulnerable neuronal populations, are implicated in cell signaling, cell cycle, immune function,
and development, and are differentially expressed in pathologically confirmed frontotemporal
lobar degeneration cases. Five of the genes highlighted by our differential expression analyses,
BAIAP2, ERBB3, POU2F2, SMARCA2, and CDC37, appear to be novel bvFTD risk loci.
Conclusions
Our findings suggest that the cumulative burden of common genetic variation in an interacting
protein network expressed in specific brain regions across the lifespan may influence suscep-
tibility to bvFTD.
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Although defined by a clear clinical syndrome, behavioral
variant frontotemporal dementia (bvFTD) is the most path-
ologically diverse form of frontotemporal lobar degeneration
(FTLD). Despite variable pathology, we and others have
shown that a shared, selectively vulnerable brain network,
composed of disparate brain regions functionally connected
throughout the lifespan, degenerates in bvFTD.1 The fact that
different protein pathologies converge on a relatively consis-
tent set of neuroanatomical regions suggests intrinsic mo-
lecular properties may predispose this network to disease.
Nevertheless, despite extensive advances in our ability to
clinically and pathologically diagnose bvFTD, little is known
about the protein networks (“nexopathies”) that drive the bi-
ological processes (BPs) underlying this selective vulnerability.2,3
New techniques enable evaluation of experimentally determined
protein networks in disease by aggregating single-nucleotide
polymorphism (SNP)-level risk metrics across an entire gene.
This technique increases statistical power, overcomes locus
heterogeneity likely to occur in clinical populations, and allows
for better detection ofmultiple variants contributing to polygenic
disease risk.4 Combining this information with existing protein
interaction data has revealed new genetic risk loci and helped
unravel the pathophysiology of complex diseases like multiple
sclerosis.5
In this study, we first generated networks of genes underlying
bvFTD risk to identify common pathophysiologic processes
underlying disease biology. Second, based on prior studies
showing that the brain network affected in bvFTD is present and
functioning throughout life,6 we evaluated spatial and temporal
risk gene expression patterns in human brain across the lifespan.
Finally, we sought to validate risk network genes using brain
tissue from patients pathologically diagnosed with FTLD.
Methods
Standard protocol approvals, registrations,
and patient consents
Written informed consent was obtained from all participants
or their guardians at the site of sample collection, and relevant
institutional review boards approved all aspects of the study.
Genome-wide association study
study participants
This study used SNP level metadata from phase 1 FTD-
GWAS data from the International FTD-Genomics
Consortium (IFGC), which was composed of 1,377 bvFTD
cases and 4,308 controls with genotypes or imputed data at
6,026,384 SNPs. Raw genetic data for each participant was not
available for analysis at the inception of this study. Cases and
controls within the cohort were diagnosed according to
published criteria for bvFTD7 by a trained neurologist or
pathologic examination.8
Gene network generation
We calculated gene-level significance values using Versatile
Gene-based Association Study (VEGAS)9 and summary data
from a recent bvFTD genome-wide association study
(GWAS).8 VEGAS assigns SNPs to their respective autosomal
genes using their position on the University of California, Santa
Cruz Genome Browser. To capture the effects of regulatory
regions and SNPs in linkage disequilibrium,10 gene boundaries
were defined as 50 kb beyond the 59 and 39 untranslated
regions of each gene. Empirical p-values for each gene were
calculated using Monte-Carlo simulations.5,9 Association
blocks were defined as groups of sequential genes with p < 0.05.
We used protein interaction network-based pathway analysis
(PINBPA) to compute first-order interactions by filtering a ref-
erence network containing 8,960 proteins and 27,724 interactions
so that only the genes (and their protein products) withVEGAS p
< 0.05were retained as significant.We evaluated network strength
using simulations, which assigned p-values to genes at random
from the parent network to create a simulated distribution of
similarly sized networks. The empirical bvFTD network’s char-
acteristics were compared against the simulated networks.
To increase resolution on the candidate proteins isolated by
the PINBPA method, we generated a second independent
network with recently developed weighted protein-protein
interaction network analysis (W-PPI-NA)11 using the 63
bvFTD genes prioritized by PINBPA as seeds. Of note, the
genes prioritized by the PINBPA analysis (CALM2 and
CALM3) were combined into one unique entry, CALM1,
through this step. We removed TrEMBL, non-protein inter-
actors (e.g., chemicals), obsolete Entrez, and Entrez matching
to multiple Swiss-Prot identifiers.
Profiling of gene expression during
development and across the human lifespan
To assess whether genes from the PINBPA networks showed
enriched expression in human brain tissues of all ages and life
stages, we used the R package ABAEnrichment and specific
Glossary
AD = Alzheimer disease; BP = biological process; CSEA = cell-type SEA; EGFR = epidermal growth factor; FDR = false-
discovery rate; bvFTD = behavioral variant frontotemporal dementia; FTLD = frontotemporal lobar degeneration;GO = gene
ontology; GWAS = genome-wide association study; IFGC = International FTD-Genomics Consortium; MAPK = mitogen-
activated protein kinase; PD = Parkinson disease; PDGF = platelet-derived growth factor; PINBPA = protein interaction
network-based pathway analysis; SEA = specific enrichment analysis; VEN = Von Economo neuron; W-PPI-NA = weighted
protein-protein interaction network analysis.
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enrichment analysis (SEA). ABAEnrichment performs ontol-
ogy gene set enrichment analyses for 26 brain regions ranging
in age from 8 postconception weeks to 40 years old from the
BrainSpan data set distributed by the Allen Brain Institute.
Forty-five percent of participants were Caucasian, 33% were
African American, 10% were Hispanic, 5% were mixed
Caucasian/African American, and 5% had no ethnicity in-
formation available. All participants were screened for neu-
rologic conditions and for large-scale chromosomal
abnormalities. Samples were grouped by age into 5 groups:
prenatal (all prenatal stages; n = 20), infant (0–2 years; n = 6),
child (3–11 years; n = 6), adolescent (12–19 years; n = 4), and
adult (older than 19 years; n = 6). Additional demographic
data are provided in table e-1 (links.lww.com/NXG/A72). All
genes evaluated in enrichment analyses were expressed above
the 10th percentile when ranked by expression. SEA allows for
expression testing across 6 brain regions and 10 different
developmental periods. Fisher’s exact test was used to assess
statistical enrichment, and false-discovery rate (FDR) cor-
rection was applied.
Cell-type-specific gene expression profiling
We used 2 RNA expression data sets examining several cell
types commonly found in the CNS, one to conduct de-
scriptive representations of the cells that most highly express
our genes of interest and the other to specifically test for
enrichment.
The first data set used gene expression from human temporal
lobe samples.12 For each gene implicated in the bvFTD net-
work, we queried the database and recorded the cell type
(fetal astrocytes, mature astrocytes, neurons, oligoden-
drocytes, microglia/macrophages, and endothelial cells) that
most highly expressed the gene of interest. The data set
represents expression across the human lifespan (18 post-
conception weeks [pcw] for fetal samples and 8–63 years old
for non-fetal samples).12
The second data set used RNAseq data from the BrainSpan
atlas to characterize cell-specific expression patterns. Enrich-
ment for specific cell types was tested using cell-type SEA
(CSEA),13 which employs expression cutoffs and tests for
cell-type-specific enrichment (CSEA employs methodology
similar to SEA). Cell types are determined using well-
validated markers,14 and enrichment is tested using Fisher’s
exact test with FDR correction.
Biological pathways and processes analysis
We classified the biological function of bvFTD network genes
using PANTHER (pantherdb.org) and Reactome (reactome.
org) to reduce the likelihood of spurious findings from any
one source. Statistical tests for overrepresentation with Bon-
ferroni correction were performed using the PANTHER
pathways annotation and Gene Ontology (GO) BPs data-
bases. We applied functional annotation analysis to the net-
work built using the 62 PINBPA-prioritized genes as seeds by
performing GO BP enrichment analyses through g:Profiler
(g:GOSt, biit.cs.ut.ee/gprofiler/15) (62 genes were used be-
cause CALM2 and CALM3 were combined into one entry as
previously described). A Fisher’s one-tailed test was used to
assess enrichment; the set counts and sizes threshold was
applied as a multiple test correction; statistical domain size
was only annotated genes; and no hierarchical filtering was
included. We then grouped enriched GO-BP terms into
custom-made “semantic classes.” We removed general, thus
negligible, semantic classes, such as general, metabolism,
enzymes, protein modification, and physiology. Semantic
classes were further grouped by similarity in more general
classes called functional blocks.
Gene expression in pathologically confirmed
FTLD cases
We analyzed gene expression data from 2 cohorts of patho-
logically confirmed FTLD along with Alzheimer disease (AD)
and Parkinson disease (PD) cases compared with normal older
adult controls. The first FTLD cohort contained 10 individuals
with pathologically confirmed sporadic FTLD, 7 individuals
with pathologically confirmed FTLD due to GRN mutations,
and 11 pathologically confirmed controls (GSE13162). The
second contained 6 FTLD cases with primarily tau pathology
(Constantinides group A), 6 FTLD cases with primarily tem-
poral atrophy and minimal tau pathology (Constantinides
group C1), and 5 normal controls (E-MEXP-2280). The AD
cohort included temporal cortex samples from 84 AD and 80
control brains (syn5550404).16 The PD cohort included sub-
stantia nigra samples from 22 PD and 23 control brains
(GSE7621).17 In linear regression analyses, we analyzed FTLD
cases together in a combined analysis and then performed
separate subgroup analyses. Following this, we analyzed the AD
and PD groups separately. In all analyses, we covaried for age,
sex, and postmortem interval.
Results
bvFTD GWAS data reveals a large protein
interaction network driven by
risk-associated alleles
Using gene-based p-values for 17,463 genes derived from the
bvFTD GWAS cohort, we identified 475 association blocks
containing a total of 1,104 genes. We next generated PINBPA
networks for the genes implicated in bvFTD. The bvFTD
network contained 63 nodes and 72 edges. Permutation
testing revealed that the bvFTD gene network was within the
top 10th percentile for nodes and edges as compared with
a sample of 1,000 randomly generated networks (figure 1 and
table e-2, links.lww.com/NXG/A73).
We then sought to analyze the topological details of the 63
PINBPA-prioritized genes by generating protein interaction
networks with our W-PPI-NA to highlight key functional
players within the identified gene set. After filtering and
scoring the protein network, the result was composed of 1,913
nodes and 3,212 edges, where all but one node, PBX2, were
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interconnected (figure 2, A). We identified the inter-
interactome hubs (IIHs; n = 10)—the proteins character-
ized by the highest connection degree distribution (figure 2, B
and C)—and we used them to define the core of the network
with the highest interconnectivity (figure 2, D). By comparing
the core of the network with randomly sampled parts of the
network, we verified that the IIHs-driven network is the most
densely connected. The core of the network was made of 52
nodes (10 IIHs and their interactors) and 121 edges; these
were strongly interconnected (average number of neighbors =
4.5), representing the proteins that keep the cohesion of
>16% of the initial seeds (n = 63; figure 2, C).
bvFTD network genes show enriched
expression in bvFTD-relevant brain regions
across the lifespan
We next tested whether genes within the bvFTD network
showed enriched or specific expression in distinct brain
regions of healthy individuals using ABAEnrichment. Hyper-
geometric tests revealed enriched expression for our bvFTD
network genes in neuroanatomical regions affected in bvFTD,
including the dorsolateral prefrontal cortex, frontal cortex,
and temporal cortex in most age groups (family-wise error
corrected p < 0.05 for each region, figure 3, A–D and table e-3,
links.lww.com/NXG/A74).
Our ABAEnrichment analyses suggested that enrichment was
most common during early life (table e-3, links.lww.com/
NXG/A74). However, they did not provide information on
the role of gene expression within the early life stages when
gene expression patterns can vary temporally and influence
neurodevelopmental processes.18 Given this, we performed
exploratory analyses using SEA and found that there were
several nominally associated regions of gene expression en-
richment concentrated within the fetal period. At a specificity
index probability level of 0.05, the amygdala (late fetal; p =
0.004), thalamus (early fetal; p = 0.006), hippocampus (late
fetal; p = 0.007), and cortex (mid-late fetal; p = 0.014) showed
nominal enrichment levels but did not withstand FDR cor-
rection (table e-4, links.lww.com/NXG/A75).
bvFTD network genes aremost highly expressed
in fetal astrocytes,mature astrocytes,microglia,
and cortical layer 5b neurons
Analysis of whole transcriptome data from specific cell types
isolated from human brain tissue12,19 revealed that the bvFTD
network genes clustered into 3 main brain cell groupings. The
most commonly observed cell type was fetal astrocytes (37%),
followed closely by neurons (35%), and microglia (20%).
bvFTD network genes were present at a lower frequency in
mature astrocytes (5%), oligodendrocytes (5%), and endo-
thelial cells (5%) (figure e-1, links.lww.com/NXG/A79).
Network genes represented only 3 of 100 and 11 of 500 of the
top-expressed genes in each cell type, suggesting that the cell
type enrichment was specific to bvFTD and not a function of
detecting genes that were most highly expressed in these cell
types. IL2 and SLA2were not expressed at a level that allowed
for reliable cell type determination.
Given our findings in the cell-type-specific expression data set,
we next used CSEA to test for enrichment of our bvFTD
network genes in specific cell types and populations. The
Figure 1 bvFTD PINBPA network
The bvFTD PINBPA network is shown.
Nodes are color coded according to
their gene-based p-value, with warmer
colors indicating lower p-values and
cooler colors representing p-values
closer to 0.05. Node size represents
closeness centrality, a measure of
a node’s nearness to other nodes
within a network. Edge thickness rep-
resents edge betweenness, a measure
of the number of paths that go through
an edge in a network.
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bvFTD network genes demonstrated enriched expression in
layer 5b neuronal cells (p = 0.038; figure e-1, links.lww.com/
NXG/A79 and table e-5, links.lww.com/NXG/A76); how-
ever, this association did not withstand FDR correction. Von
Economo neurons (VENs) and fork cells, which are among
the earliest cells to degenerate in bvFTD, are located within
layer 5b.20
Ontological analyses reveal
overrepresentation of immune signaling
in bvFTD risk genes
Functional (ontological) characterization of the 63 bvFTD
network genes indicated overrepresentation of immune-
mediated pathways, cell signaling, cell cycle, and de-
velopment (table 1). Reactome analysis indicated the
greatest degree of overrepresentation in pathways known to
be involved with microglia-initiated inflammatory respon-
ses, such as epidermal growth factor (EGFR) signaling,
mitogen-activated protein kinases (MAPKs), and
pro-inflammatory cytokines (IL-3, IL-5, granulocyte-
macrophage colony-stimulating factor [GM-CSF]) (table
e-6, links.lww.com/NXG/A77). PANTHER analysis found
similar overrepresentation for interleukin signaling path-
ways, EGFR signaling, and platelet-derived growth factor
(PDGF) signaling.
We evaluated additional GO BPs via g:Profiler for the second
protein network built by W-PPI-NA and focused on the
interactomes of the 63 genes prioritized through the PINBPA
protocol. This first functional enrichment was followed by
a second iteration performed only on the core of the
network—i.e., defined by the IIHs and their interactors—thus
containing the most densely connected proteins. Functional
annotation of the latter indicated a list of semantic classes that
were a subset of the former: of interest, the subset terms
(percentage of retention >15%) pointed to the following
functional blocks: (1) “development”; (2) “motility”; (3)
“protein modification”; and (4) “cell signaling” (figure e-2,
links.lww.com/NXG/A80). These appeared as the common
functions characterizing the part of the protein network with
Figure 2 Interactome analyses in bvFTD
(A) Protein network built through the W-PPI-NA pipeline around the 63 genes prioritized by the PINBPA protocol. The seeds are depicted in pink and their
interactors in blue. (B) Inter-interactome degree distribution curve reporting the number of nodes (x-axis) able to bridge an N number of seeds (y-axis). The
IIHs are the nodes marked by the rectangle. (C) List of IIHs reporting the number of seeds that they bridge and associated %. *UBC has been reported yet
ignored as it is likely a false positive (as it may indicate unspecific binding of ubiquitin to proteins tagged for degradation). (D) Core of the network around the
IIHs, which are depicted in pink.
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strongest cohesion among the initial seeds. In particular, the
functional block “development” contained semantic classes
referring to cell differentiation and proliferation as well as glial
and neuronal cell development, while the functional block
“cell signaling” contained semantic classes referring to the
previously mentioned MAPK, PDGF, and immune-specific
signaling in addition to terms related to Fc (typically relevant
for immune cells), ERBB (relevant for both developmental
and immune processes), growth factors, and hormone-based
signaling events. These findings confirmed the PANTHER
and Reactome results, using a completely independent
approach.
bvFTD network genes are dysregulated
in postmortem brain tissue
To examine whether the risk-associated genes identified by
the network analysis are differentially expressed in human
disease, we assessed the expression patterns of our bvFTD
genes in postmortem samples from 2 pathologically con-
firmed cohorts of FTLD cases along with AD16 and PD17
cases compared with pathology-free controls. In the first
FTLD cohort, GSE13162, 61 bvFTD genes had expression
data available. In the second FTLD cohort, E-MEXP-2280,
there were 58 bvFTD genes with expression data available.
Because the 2 data sets represent a mix of sporadic and
autosomal dominant (GRN) postmortem cases (GSD13162)
or sporadic cases with tau and non-tau pathology (E-MEXP-
2280), we analyzed data in aggregate and by gene status or
pathologic subtype (table e-7, links.lww.com/NXG/A78). In
GSE13162, 19 bvFTD genes were differentially expressed
between cases vs controls (PFDR < 0.05). In E-MEXP-2280,
26 bvFTD genes were differentially expressed (PFDR < 0.05).
Of these top genes, 9 (BAIAP2, CALD1, CDC37, ERBB3,
GSK3A, MAP3K5, POU2F2, SMARCA2, and TGFB1|1)
showed dysregulation in both cohorts (table 2 and table e-7).
Several of these genes appear to be novel risk factors for
bvFTD (table 2). In AD cases, 7 of 9 bvFTD network genes
were differentially expressed (table 2). In contrast, 0 of 9 net-
work genes were differentially expressed in PD cases (table 2).
Discussion
We identified a network of interacting bvFTD risk genes that
demonstrate enriched expression in bvFTD-affected brain
regions and cell types across the human lifespan. Differential
expression analyses in pathologically confirmed cases of
FTLD and controls showed that many of our network genes
were dysregulated in pathologically confirmed FTLD, and 5
potentially novel bvFTD risk genes showed altered expression
Figure 3 Regional gene expression enrichment across the lifespan
For each of the 5 age groups used in the ABAEnrichment analyses, we counted the number of times each of the 26 available brain regions showed enrichment
of the bvFTD network genes. The superior temporal cortex was the most common region of enriched expression with 5 observations (i.e., in every age
grouping). Generally, the FTD cohort showed enriched expression in both frontal (DFC, VFC, M1C, PFC, OFC) and temporal (A1C, ITC, STC, MFC) regions. (A and
B) The number of times each region was associated is illustrated on a model brain. Brain regions were mapped onto the illustration using information
provided in Bahl et al. 2017. When regional overlap was detected (e.g., IPC is contained within PCx or DFC; VFC and OFC are contained within PFC), the more
specific region(s) was chosen for presentation. (C) A graphical depiction of the data shown in (A and B). The number of times each brain regionwas associated
from the 5 age groupings is shown. (D) Detailed results are shown in a table formatwith age groupings as rows and brain regions as columns. Regions shaded
in black were statistically associated while unshaded regions were not. A1C = primary auditory cortex; AMY = amygdaloid complex; CN = cerebral nuclei; CB =
cerebellum; CBC = cerebellar cortex; DFC = dorsolateral prefrontal cortex; HIP = hippocampus; IPC = posteroventral (inferior) parietal cortex; ITC = infero-
lateral temporal cortex; M1C = primary motor cortex; MFC = anterior (rostral) cingulate (medial prefrontal) cortex; OFC = orbital frontal cortex; PCx = parietal
neocortex; PFC = prefrontal cortex; S1C = primary somatosensory cortex; STC = posterior (caudal) superior temporal cortex; STR = striatum; TCx = temporal
neocortex; THA = thalamus; V1C = primary visual cortex; VFC = ventrolateral prefrontal cortex.
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in both pathologic cohorts. Taken together, our results pro-
vide evidence that the pathologic heterogeneity seen in
bvFTD may occur as the product of multiple dysregulated
cellular pathways that converge on specific brain networks
across the lifespan. Our findings also contribute to the mo-
lecular understanding of selective vulnerability in bvFTD and
suggest several potential mechanisms by which genetic vari-
ation and gene expression abnormalities increase
susceptibility to neurodegenerative diseases like bvFTD. Our
analyses suggest that this bvFTD risk gene network may
overlap with AD, a related disorder sharing genetic risk fac-
tors23 and tau pathology24 that can also present with
a bvFTD-like syndrome.25 Additional analyses will be useful
to elucidate the specificity of these findings to bvFTD com-
pared with AD and determine any shared mechanisms con-
ferring risk across other neurodegenerative diseases.
Table 1 Pathway analysis in bvFTD network genes
Biological
pathway Pathway
No. of genes
reference,
candidate
data set Candidate genes mapped
Fold
enriched p Value Database
Immune
system
Interleukin signaling pathway 98, 5 IL-2, MYC, SLA2, SHC1, IRS2 17.26 1.83 × 10−3 PANTHER
Interleukin 3, 5, and GM-CSF 250, 8 IL-2, RET, GDNF, SHC1, SHC3, IRS2, LYN, CBL 10.82 1.38 × 10−3 Reactome
Fc gamma receptor
phagocytosis
90, 5 FCGR2A, HSP90AA1, BAIAP2, FCGR3A, VAV2 18.79 0.01 Reactome
GP VI mediated activation
cascade
55, 4 IL-2, SHC1, LYN, VAV2 24.60 0.04 Reactome
Cell signaling
EGF receptor signaling pathway 139, 6 SHC1, SHC3, CBL, ERBB4, ERBB3, MAP3K5 11.61 5.99 × 10−4 PANTHER
14, 4 SHC1, CBL, CDC37, HSP90AA1 96.65 1.19 × 10−4 Reactome
ERBB2 43, 4 CDC37, HSP90AA1, SHC1, PTPN12 31.47 0.02 Reactome
ERBB4 315, 8 IL2, RET, ESR1, GDNF, SHC1, SHC3, IRS2, GSK3A 8.59 7.55 × 10−3 Reactome
VEGF signaling 307, 9 IL2, RET, GDNF, SHC1, SHC3, IRS2, HSP90AA1,
BAIAP2, VAV2
9.92 5.52 × 10−4 Reactome
MAPK signaling 229, 7 IL2, RET, TYK2, GDNF, SHC1, SHC3, IRS2 10.34 9.55 × 10−3 Reactome
FCERI-mediated MAPK
activation
276, 8 IL2, RET, GDNF, SHC1, SHC3, IRS2, LYN, VAV2 9.80 2.87 × 10−3 Reactome
DAP12 signaling 330, 8 IL2, RET, GDNF, SHC1, SHC3, IRS2, GSK3A, VAV2 8.20 0.01 Reactome
Cell cycle
Cyclin A CDK2-associated
events at S phase entry
70, 5 MYC, CDK2, CDC25B, CKS1B, MNAT1 24.16 4.06 × 10−3 Reactome
G1/S transition 139, 6 MYC, CKS1B, MNAT1, CDK2, CDC6, CDK6 14.6 6.73 × 10−3 Reactome
Development/
growth
FGFR signaling 318, 8 IL2, RET, GDNF, SHC1, SHC3, IRS2, GSK3A, CBL 8.51 8.09 × 10−3 Reactome
Signaling by SCF-KIT 311, 9 IL2, RET, GDNF, SHC1, SHC3, IRS2, GSK3A, LYN,
CBL
9.79 6.14 × 10−4 Reactome
Developmental biology 806, 11 VAV2, LYN, HIST2H2BE, HSP90AA1, IRS2, SHC3,
SHC1, NCOR2M, GDNF, RET, IL2
4.62 0.04 Reactome
Platelet-derived growth factor
signaling pathway
149, 5 MYC, SHC1, SHC3, GSK3A, VAV2 11.35 0.01 PANTHER
Abbreviations: bvFTD = behavioral variant frontotemporal dementia; DAP = DNAX-activation protein; EGF = epidermal growth factor; FCERI = Fc epsilon
receptor; FGFR = fibroblast growth factor receptor; GM-CSF = granulocyte-macrophage colony-stimulating factor; GP VI = Glycoprotein VI; MAPK = mitogen-
activated protein kinase; SCF = stem cell factor; VEGF = vascular endothelial growth factor.
Pathway analysis results are shown. For each broad biological pathway, specific pathways from PANTHER and Reactome databases are provided. In all
analyses, the p-value presented has been adjusted using the Bonferroni technique, which is the default setting for both PANTHERandReactome. See table e-6
(links.lww.com/NXG/A77) for additional details.
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Table 2 Differentially expressed genes enriched in both FTLD pathologic cohorts
Gene
symbol
Chen-Plotkin et al.21 Bronner et al.22 Allen et al.16 and Lesnick et al.17
Disease
associations
Combined analyses Split by GRN genotype Combined analyses Split by pathologic diagnosis Disease comparisons
Bronner Bronner
GRN +
Praw
GRN +
PFDR
GRN 2
Praw
GRN 2
PFDR Praw PFDR
Type
C1 Praw
Type
C1 PFDR
Type
A Praw
Type
A PFDR AD Praw AD PFDR
PD
Praw
PD
PFDR
BAIAP2a 6.28 × 10−3 0.03 0.56 0.65 2.35 × 10−4 2.43 × 10−3 7.48 × 10−3 0.05 0.02 0.45 0.08 0.32 2.75 × 10−6 8.41 × 10−5 0.08 0.51 AD,34 autism, ADHD35
CALD1 5.84 × 10−4 0.01 3.64 × 10−4 7.51 × 10−3 4.31 × 10−3 0.02 8.78 × 10−3 0.05 0.19 0.69 0.03 0.32 1.60 × 10−7 1.12 × 10−5 0.05 0.36 ALS, AD, FTLD36
ERBB3a 3.54 × 10−3 0.02 2.87 × 10−3 0.02 0.02 0.06 7.50 × 10−3 0.05 0.22 0.7 0.07 0.32 0.64 0.72 0.10 0.54 PD37
GSK3A 3.20 × 10−4 9.05 × 10−3 0.01 0.04 6.15 × 10−4 5.08 × 10−3 2.67 × 10−3 0.04 0.19 0.69 0.04 0.32 1.43 × 10−3 8.53 × 10−3 0.22 0.75 FTLD,38 AD39
MAP3K5 2.59 × 10−3 0.02 9.20 × 10−3 0.03 0.03 0.09 3.97 × 10−3 0.04 0.17 0.69 2.77 × 10−3 0.14 2.77 × 10−6 8.44 × 10−5 0.42 0.86 ALS, FTLD,
Huntington40
POU2F2a 8.51 × 10−4 0.01 0.17 0.27 7.24 × 10−5 1.43 × 10−3 5.68 × 10−5 4.29 × 10−3 0.01 0.45 2.65 × 10−3 0.14 1.07 × 10−3 6.98 × 10−3 0.18 0.68 —
SMARCA2a 2.63 × 10−3 0.02 0.32 0.43 1.32 × 10−4 1.93 × 10−3 8.90 × 10−3 0.05 0.24 0.7 0.06 0.32 0.41 0.52 0.10 0.55 Nicolaides-Braitser
syndrome41
CDC37a 0.01 0.05 5.31 × 10−4 7.51 × 10−3 0.19 0.33 4.83 × 10−5 4.29 × 10−3 2.97 × 10−3 0.45 0.01 0.31 2.28 × 10−3 0.01 0.61 0.91 AD42
TGFB1I1 8.84 × 10−3 0.04 1.37 × 10−3 0.01 0.08 0.18 6.79 × 10−3 0.05 0.11 0.68 5.09 × 10−3 0.19 2.85 × 10−3 0.01 0.87 0.96 AD,43 FTD44
Abbreviations: AD = Alzheimer disease; ADHD = attention-deficit/hyperactivity disorder; ALS = amyotrophic lateral sclerosis; FDR = false-discovery rate; FTD = frontotemporal dementia; FTLD = frontotemporal lobar
degeneration; PD = Parkinson disease.
Results are shown for differential expression analyses in 2 pathologically confirmed FTLD cohorts along with AD and PD for comparison. Nine genes were differentially expressed in the 2 cohorts: BAIAP2, CALD1, CDC37, ERBB3,
GSK3A, MAP3K5, POU2F2, SMARCA2, CDC37, and TGFB1I1. For each public data source, the publication reference is provided.
a Indicates to the best of our knowledge not previously reported in FTLD.
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By integrating GWAS with protein interaction data, gene
expression data from across the lifespan, and postmortem
gene expression data from confirmed FTLD cases, we high-
light the importance of bvFTD risk genes during de-
velopment, aging, and disease. Our network genes showed
enrichment in regions of the brain commonly affected in
bvFTD such as the dorsolateral and ventrolateral prefrontal
cortices, and inferior temporal cortex (figure 3). Because of
the scarcity of pathologic samples available for enrichment
analyses, some regions of the brain that have known roles in
bvFTD, such as the cingulate and insula, were not available for
analysis. Of interest, our genes also showed enrichment in
brain regions typically spared in bvFTD patients such as su-
perior temporal cortex, occipital cortex, and sensory cortex.
Although the reason for this enrichment remains to be de-
termined, it is possible that spared regions contain similar cell
types as vulnerable ones but remain unaffected because they
are functionally disconnected from pathologically affected
regions in bvFTD and remain unexposed to pathologic
aggregates that may disseminate through functionally con-
nected neural networks.26,27 Alternatively, and perhaps
counterintuitively, consistently enriched expression (and
thereby greater expression across the lifespan) of bvFTD
network genes in regions like cerebellum and superior tem-
poral cortex could potentially provide protection against
neurodegenerative processes. In this framework, reduced ex-
pression of the same genes in other, less-enriched, brain
regions may result in vulnerability to disease pathology be-
cause less-enriched brain regions have less “reserve” expres-
sion to rely on during aging, potentially reducing the
threshold within which variable expression is tolerated by
relevant biological systems.
An exploratory analysis revealed that our bvFTD network
genes are most highly expressed in fetal astrocytes, neurons,
and microglia/macrophages. The importance of fetal astro-
cytes is particularly interesting in the context of our pathway
findings as they are implicated in neurodevelopmental pro-
cesses, complement signaling, and forming healthy neuronal
synapses.28 Many of the identified bvFTD risk genes were
most highly expressed in neuronal populations, which par-
ticipate in many of the cell signaling pathways highlighted in
our GO analyses.29 Neurons may also be the target of ab-
normal expression of cell-cycle regulation proteins, which
have been shown in studies of neurodegenerative diseases
to result in apoptosis when activated.30,31 The third major
cell type expressing our genes of interest—microglia/
macrophages—play an increasingly appreciated role in the
pathogenesis of bvFTD and other neurodegenerative dis-
orders.32 Remarkably, our CSEA analyses highlighted layer 5b
cortical neurons as sites of bvFTD network gene expression
enrichment. Pathologic evidence in human brain tissue sug-
gests this cortical layer as a likely site of selectively vulnerable
neuronal populations in bvFTD (VENs and fork cells).33
While this finding was not significant after correction for
multiple testing, it is striking for its convergence on the site of
bvFTD neurodegeneration in the cortex and provides a strong
impetus for further study of bvFTD risk gene expression
patterns in these specific cell populations.
Limitations of this study include lack of a suitable case-control
data set of sufficient size to confirm whether our network and
risk loci are associated with disease risk and lack of access to
raw IFGC genotype data to perform subgroup analyses. Phase
III data of the IFGC (on over 2,000 new cases) will be re-
leased in the near future and that cohort could represent
a suitable cohort for validation of these findings and further
characterization efforts. Our data-sharing agreement with the
IFGC provided SNP-level GWAS results only and we did not
have raw genetic data, which precludes potentially more
powerful study designs, such as subsetting the cohort into
training and testing data sets. Beyond this, our network gen-
eration methodology relies on already existing protein in-
teraction data and thus could bias our ontological findings
toward more thoroughly characterized biological pathways
and processes. An additional limitation of our gene expression
analyses stems from Constantinidis diagnoses, which are not
easily converted into more modern pathologic diagnoses.
In our analyses, we identified and bioinformatically charac-
terized a gene network linked at the protein level that shows
enriched expression across the human lifespan in brain areas
most affected by bvFTD and shows dysregulation in patho-
logically diagnosed FTLD cases. These findings suggest that
multiple distinct biological pathways are altered in sporadic
bvFTD, including signal transduction, cell cycle regulation,
immune/inflammation, and neurodevelopmental processes.
Together, these pathway enrichments raise an important and
unanswered question regarding the temporal relationship
between genetic variation and biological risk for disease. It is
plausible that a subset of risk variants promotes disease risk
specifically during development, while others promote risk
through nuanced changes in biological function in aging. It is
also possible that genetic variation may be helpful during
development but detrimental during aging if activated in-
appropriately (e.g., synaptic pruning by the innate immune
system). Future longitudinal studies of at-risk individuals will
be required to fully address this question. Although no single
genetic variant used to generate our network directly causes
bvFTD, the cumulative burden of multiple sub-GWAS-
associated variants within these pathways may alter the cel-
lular landscape on which development and aging occurs,
thereby altering the amount of metabolic stress, inflammation,
and apoptotic tendencies of particular cell types in defined
brain networks. Our results support the utility of polygenic
scores that incorporate the effects of multiple genetic loci for
clinical risk assessment and prevention study enrichment, and
genetic overlap with AD suggests shared underlying biology
across multiple neurodegenerative disorders. Understanding
the temporal tropism of these risk factors on disease vulner-
ability will also be critical for translating these results into
therapeutic targets for clinical populations, especially for
processes such as metabolic stress and immune dysfunction
that are more amenable to intervention. If confirmed, our
Neurology.org/NG Neurology: Genetics | Volume 4, Number 5 | October 2018 9
findings represent a valuable step toward a genetic un-
derstanding of selective vulnerability in neurodegenerative
disease.
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